To determine whether sequential doses of GEM increased tumor-antigen specific LAG3+ CD8+ TPEX in vivo, we transferred CD8+ TCR transgenic cells from CL4xThy1.1 mice into recipient BALB/c mice prior to inoculation of AB1-HA and tracked tumor-antigen (HA) specific CD8+ T cells by allelic marker Thy1.1.31 Here, CD8A is linked to neoplasm.